$AMR
Alpha Metallurgical Resources, Inc. Stock $amr

$amr Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000170471523000066 Filed on November 02, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$960.0M	$741.8M
YoY Change	16.58%	-14.71%
Cost Of Revenue	$668.9M	$564.6M
YoY Change	21.78%	1.64%
Gross Profit	$291.1M	$177.2M
YoY Change	6.17%	-43.61%
Gross Profit Margin	30.32%	23.89%
Selling, General & Admin	$26.14M	$18.05M
YoY Change	12.29%	19.6%
% of Gross Profit	8.98%	10.19%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$44.70M	$34.70M
YoY Change	63.21%	6.87%
% of Gross Profit	15.36%	19.58%
Operating Expenses	$77.79M	$18.05M
YoY Change	30.95%	19.6%
Operating Profit	$213.3M	$117.2M
YoY Change	-0.68%	-55.12%
Interest Expense	-$5.260M	$1.746M
YoY Change	-13.19%	3.01%
% of Operating Profit	-2.47%	1.49%
Other Income/Expense, Net	-$763.0K	-$4.381M
YoY Change	-139.17%	16.83%
Pretax Income	$204.5M	$112.8M
YoY Change	-3.7%	-56.16%
Income Tax	$28.53M	$18.96M
% Of Pretax Income	13.95%	16.82%
Net Earnings	$176.0M	$93.81M
YoY Change	-20.24%	-62.89%
Net Earnings / Revenue	18.34%	12.65%
Basic Earnings Per Share		$6.88
Diluted Earnings Per Share	$12.89	$6.65
COMMON SHARES
Basic Shares Outstanding	13.28M shares	13.69M shares
Diluted Shares Outstanding		14.11M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$268.2M	$302.8M
YoY Change	-22.91%	-25.13%
Cash & Equivalents	$268.2M	$296.1M
Short-Term Investments	$32.00K	$6.700M
Other Short-Term Assets	$39.03M	$41.90M
YoY Change	-75.4%	-45.62%
Inventory	$231.3M	$271.8M
Prepaid Expenses
Receivables	$509.7M	$432.4M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.048B	$1.049B
YoY Change	-5.93%	-8.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.044B	$986.3M
YoY Change	16.25%	19.13%
Goodwill	$11.12M
YoY Change	3.61%
Intangibles	$46.58M	$48.64M
YoY Change	-15.47%	-16.93%
Long-Term Investments	$31.67M
YoY Change	37.28%
Other Assets	$106.5M	$105.7M
YoY Change	3.19%	13.3%
Total Long-Term Assets	$1.358B	$1.304B
YoY Change	13.33%	17.22%
TOTAL ASSETS
Total Short-Term Assets	$1.048B	$1.049B
Total Long-Term Assets	$1.358B	$1.304B
Total Assets	$2.406B	$2.353B
YoY Change	4.05%	4.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$128.8M	$121.5M
YoY Change	21.5%	19.58%
Accrued Expenses	$113.0M	$115.8M
YoY Change	-0.76%	-16.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.582M	$3.400M
YoY Change	16.37%	98.71%
Total Short-Term Liabilities	$309.9M	$315.2M
YoY Change	-23.02%	-7.66%
LONG-TERM LIABILITIES
Long-Term Debt	$6.792M	$7.100M
YoY Change	-13.99%	137.7%
Other Long-Term Liabilities	$18.62M	$18.22M
YoY Change	-7.8%	-12.37%
Total Long-Term Liabilities	$18.62M	$18.22M
YoY Change	-7.8%	-12.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$309.9M	$315.2M
Total Long-Term Liabilities	$18.62M	$18.22M
Total Liabilities	$832.1M	$794.9M
YoY Change	-5.73%	-10.5%
SHAREHOLDERS EQUITY
Retained Earnings	$1.970B	$1.800B
YoY Change	54.43%	57.58%
Common Stock	$221.0K	$220.0K
YoY Change	1.84%	1.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.574B	$1.558B
YoY Change
Total Liabilities & Shareholders Equity	$2.406B	$2.353B
YoY Change	4.05%	4.12%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$176.0M	$93.81M
YoY Change	-20.24%	-62.89%
Depreciation, Depletion And Amortization	$44.70M	$34.70M
YoY Change	63.21%	6.87%
Cash From Operating Activities	$199.4M	$157.2M
YoY Change	7.78%	-68.37%
INVESTING ACTIVITIES
Capital Expenditures	$61.54M	$54.70M
YoY Change	0.95%	-264.07%
Acquisitions
YoY Change
Other Investing Activities	$22.17M	-$600.0K
YoY Change	-125.83%	-71.1%
Cash From Investing Activities	-$39.36M	-$55.30M
YoY Change	-73.18%	56.15%
FINANCING ACTIVITIES
Cash Dividend Paid		$7.001M
YoY Change		3.37%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-154.9M	-106.5M
YoY Change	12.48%	-47.57%
NET CHANGE
Cash From Operating Activities	199.4M	157.2M
Cash From Investing Activities	-39.36M	-55.30M
Cash From Financing Activities	-154.9M	-106.5M
Net Change In Cash	5.062M	-4.600M
YoY Change	-105.08%	-101.78%
FREE CASH FLOW
Cash From Operating Activities	$199.4M	$157.2M
Capital Expenditures	$61.54M	$54.70M
Free Cash Flow	$137.8M	$102.5M
YoY Change	11.13%	-80.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	AMR
	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q3	amr	Acquisition Related Obligations Changes In Fair Value Gain Loss AcquisitionRelatedObligationsChangesInFairValueGainLoss	0	usd
CY2022Q3	amr	Acquisition Related Obligations Changes In Fair Value Gain Loss AcquisitionRelatedObligationsChangesInFairValueGainLoss	2954000	usd
	amr	Acquisition Related Obligations Changes In Fair Value Gain Loss AcquisitionRelatedObligationsChangesInFairValueGainLoss	0	usd
	amr	Acquisition Related Obligations Changes In Fair Value Gain Loss AcquisitionRelatedObligationsChangesInFairValueGainLoss	-10615000	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-973000	usd
CY2022Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2713000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1665000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-569000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	624661000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	607298000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	1861663000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	262470000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	1746000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4821000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-614000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22427000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	640913000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1341818000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5730000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94973000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	113953000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	93814000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	252817000	usd
	us-gaap	Net Income Loss NetIncomeLoss	545940000	usd
	us-gaap	Net Income Loss NetIncomeLoss	1227865000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.88
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	37.87
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	68.14
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.65
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	14.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	36.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	65.31
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13633640	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17119328	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14416289	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18019161	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14110488	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17718517	shares
	us-gaap	Net Income Loss NetIncomeLoss	545940000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1225482000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	301906000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	46052000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	239000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	407210000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	200574000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	84748000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	24547000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	49384000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1114421000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	491186000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	442645000	usd
CY2022Q4	us-gaap	Mineral Properties Accumulated Depletion MineralPropertiesAccumulatedDepletion	77333000	usd
CY2022Q4	us-gaap	Mineral Rights MineralRights	451062000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	53719000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	55102000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	105735000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	28941000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	11378000	usd
CY2022Q4	us-gaap	Assets Assets	2312479000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	3078000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	106037000	usd
CY2022Q4	amr	Acquisition Related Obligations Carrying Amount Current AcquisitionRelatedObligationsCarryingAmountCurrent	28254000	usd
CY2022Q4	amr	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	265256000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	402625000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	7897000	usd
CY2022Q4	amr	Liability Defined Benefit Plan Postretirement Black Lung Health Coverage And Workers Compensation Noncurrent LiabilityDefinedBenefitPlanPostretirementBlackLungHealthCoverageAndWorkersCompensationNoncurrent	188247000	usd
CY2022Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	110836000	usd
CY2022Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	142048000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22000000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13400000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21700000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15500000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	217000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	815442000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12162000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	6200000	shares
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1585000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7757000	usd
	amr	Acquisition Related Obligations Changes In Fair Value Gain Loss AcquisitionRelatedObligationsChangesInFairValueGainLoss	0	usd
	amr	Acquisition Related Obligations Changes In Fair Value Gain Loss AcquisitionRelatedObligationsChangesInFairValueGainLoss	-10615000	usd
	amr	Gain Loss On Disposition Of Assets Including Cost Of Sales GainLossOnDispositionOfAssetsIncludingCostOfSales	6089000	usd
	amr	Gain Loss On Disposition Of Assets Including Cost Of Sales GainLossOnDispositionOfAssetsIncludingCostOfSales	2607000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	19129000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	17822000	usd
	us-gaap	Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash	9989000	usd
	us-gaap	Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash	1312000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	27898000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9678000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4103000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-11582000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8318000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-123000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	432000	usd
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	68472000	usd
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	87714000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	651806000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1299037000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	183836000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	103351000	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	7855000	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3010000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	11919000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	166515000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	181539000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	249598000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	117380000	usd
	amr	Payments To Acquire Equity Method Investments Capital Contributions PaymentsToAcquireEquityMethodInvestmentsCapitalContributions	21844000	usd
	amr	Payments To Acquire Equity Method Investments Capital Contributions PaymentsToAcquireEquityMethodInvestmentsCapitalContributions	13832000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-24000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23669000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	272340000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	454954000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	2059000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	2083000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11618000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10527000	usd
CY2022Q1	amr	Share Based Compensation Issuance Of Stock For Share Vesting And Stock Reissuance ShareBasedCompensationIssuanceOfStockForShareVestingAndStockReissuance	1182000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	891000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3039000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	929847000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	574157000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3976000	usd
CY2022Q2	amr	Share Based Compensation Issuance Of Stock For Share Vesting And Stock Reissuance ShareBasedCompensationIssuanceOfStockForShareVestingAndStockReissuance	1401000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	usd
CY2022Q2	amr	Treasury Stock Value Acquired Cost Method And Related Expenses TreasuryStockValueAcquiredCostMethodAndRelatedExpenses	192958000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	18068000	usd
CY2022Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.375
CY2022Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	6977000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1319573000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	1746000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4639000	usd
CY2023Q3	amr	Adjusted Earnings Before Income Tax Interest Depreciation And Amortization AdjustedEarningsBeforeIncomeTaxInterestDepreciationAndAmortization	153911000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	252817000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1754000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1058000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5730000	usd
CY2022Q3	amr	Depreciation Depletion And Amortization Excluding Acquired Intangibles DepreciationDepletionAndAmortizationExcludingAcquiredIntangibles	27925000	usd
CY2022Q3	amr	Noncash Allocated Sharebased Compensation Expense NoncashAllocatedSharebasedCompensationExpense	1520000	usd
CY2022Q3	amr	Acquisition Related Obligations Changes In Fair Value Gain Loss AcquisitionRelatedObligationsChangesInFairValueGainLoss	2954000	usd
CY2022Q3	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	5921000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4543000	usd
CY2022Q3	amr	Adjusted Earnings Before Income Tax Interest Depreciation And Amortization AdjustedEarningsBeforeIncomeTaxInterestDepreciationAndAmortization	296198000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3M
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	117159000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1412000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6660000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14973168	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18800674	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	93814000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	252817000	usd
	us-gaap	Net Income Loss NetIncomeLoss	1227865000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent	581000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent	-818000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent	5373000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent	2383000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent	129000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent	1192000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-452000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103195000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10874000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20197000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	882724000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	649061000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1275319000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1429755000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2312479000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6458000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	11406000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4232000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-126637000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-182564000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1686000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	450484000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	99731000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	6807000	usd
	amr	Payments For Repurchase Of Common Stock And Related Expenses PaymentsForRepurchaseOfCommonStockAndRelatedExpenses	403385000	usd
	amr	Payments For Repurchase Of Common Stock And Related Expenses PaymentsForRepurchaseOfCommonStockAndRelatedExpenses	391166000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4322000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4771000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1020000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-447000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-501500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-844133000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	379063000	usd
	amr	Accrued Common Stock Repurchases AccruedCommonStockRepurchases	6275000	usd
	amr	Accrued Common Stock Repurchases AccruedCommonStockRepurchases	5864000	usd
CY2023Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	9418000	usd
CY2022Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	6898000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296059000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	404430000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	18800000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	83004000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	31724000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	379063000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	454954000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	546909000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	400891000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	775000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	252817000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	818000	usd
CY2022Q3	amr	Share Based Compensation Issuance Of Stock For Share Vesting And Stock Reissuance ShareBasedCompensationIssuanceOfStockForShareVestingAndStockReissuance	1520000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	270000	usd
CY2022Q3	amr	Treasury Stock Value Acquired Cost Method And Related Expenses TreasuryStockValueAcquiredCostMethodAndRelatedExpenses	198564000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1964000	usd
CY2022Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.392
CY2022Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	6729000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1371669000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1429755000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	270771000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-488000	usd
CY2023Q1	amr	Share Based Compensation Issuance Of Stock For Share Vesting And Stock Reissuance ShareBasedCompensationIssuanceOfStockForShareVestingAndStockReissuance	3034000	usd
CY2023Q1	amr	Treasury Stock Value Acquired Cost Method And Related Expenses TreasuryStockValueAcquiredCostMethodAndRelatedExpenses	148973000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1301000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.44
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	6825000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1548575000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	181355000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3241000	usd
CY2023Q2	amr	Share Based Compensation Issuance Of Stock For Share Vesting And Stock Reissuance ShareBasedCompensationIssuanceOfStockForShareVestingAndStockReissuance	3645000	usd
CY2023Q2	amr	Treasury Stock Value Acquired Cost Method And Related Expenses TreasuryStockValueAcquiredCostMethodAndRelatedExpenses	157645000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1278000	usd
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2023Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	7233000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1566734000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	93814000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-452000	usd
CY2023Q3	amr	Share Based Compensation Issuance Of Stock For Share Vesting And Stock Reissuance ShareBasedCompensationIssuanceOfStockForShareVestingAndStockReissuance	2999000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	225000	usd
CY2023Q3	amr	Treasury Stock Value Acquired Cost Method And Related Expenses TreasuryStockValueAcquiredCostMethodAndRelatedExpenses	102394000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4110000	usd
CY2023Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2023Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	6963000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1558073000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	ReclassificationsCertain immaterial amounts for the three and nine months ended September 30, 2022 in the Condensed Consolidated Financials Statements and notes to the Condensed Consolidated Financials Statements have been recast to reclassify discontinued operations and present the related amounts within continuing operations as part of the All Other category.
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	71365000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	85187000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	156552000	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1240	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	93814000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	252817000	usd
	us-gaap	Net Income Loss NetIncomeLoss	545940000	usd
	us-gaap	Net Income Loss NetIncomeLoss	1227865000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13633640	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17119328	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14416289	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18019161	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.88
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	37.87
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	68.14
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13633640	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17119328	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14416289	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18019161	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	31667	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	170827	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	108469	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	312395	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14110488	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17718517	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14973168	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18800674	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.65
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	14.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	36.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	65.31
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	53762000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	57382000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	156715000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	91474000	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	61328000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	51718000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	271805000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	200574000	usd
CY2023Q1	amr	Stock Repurchase Program Additional Authorized Repurchase Amount StockRepurchaseProgramAdditionalAuthorizedRepurchaseAmount	200000000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	1200000000	usd
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	5976397	shares
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	910281000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	910101000	usd
	amr	Stock Repurchase Program Expenses StockRepurchaseProgramExpenses	180000	usd
CY2023Q3	amr	Stock Repurchase Program Excise Tax StockRepurchaseProgramExciseTax	3482000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.44
CY2023Q2	us-gaap	Payments Of Dividends PaymentsOfDividends	6602000	usd
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2023Q3	us-gaap	Payments Of Dividends PaymentsOfDividends	7001000	usd
CY2023Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
	amr	Dividend Equivalent DividendEquivalent	682000	usd
CY2023Q3	amr	Deposits Dividends DepositsDividends	6736000	usd
CY2016Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	810811	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	45.086
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	44.972
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	44.820
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1.20	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2023Q3	amr	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	96556	shares
	amr	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	169028	shares
CY2023Q3	amr	Shares Withheld Upon Conversion Of Convertible Securities SharesWithheldUponConversionOfConvertibleSecurities	4978	shares
	amr	Shares Withheld Upon Conversion Of Convertible Securities SharesWithheldUponConversionOfConvertibleSecurities	20139	shares
CY2023Q3	amr	Shares Withheld Upon Conversion Of Convertible Securities Reclassified As Treasury Stock Value SharesWithheldUponConversionOfConvertibleSecuritiesReclassifiedAsTreasuryStockValue	577000	usd
	amr	Shares Withheld Upon Conversion Of Convertible Securities Reclassified As Treasury Stock Value SharesWithheldUponConversionOfConvertibleSecuritiesReclassifiedAsTreasuryStockValue	2368000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	211477	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	245313	shares
CY2022Q3	amr	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	60084	shares
	amr	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	678241	shares
CY2022Q3	amr	Shares Withheld Upon Conversion Of Convertible Securities SharesWithheldUponConversionOfConvertibleSecurities	18151	shares
	amr	Shares Withheld Upon Conversion Of Convertible Securities SharesWithheldUponConversionOfConvertibleSecurities	186397	shares
CY2022Q3	amr	Shares Withheld Upon Conversion Of Convertible Securities Reclassified As Treasury Stock Value SharesWithheldUponConversionOfConvertibleSecuritiesReclassifiedAsTreasuryStockValue	1680000	usd
	amr	Shares Withheld Upon Conversion Of Convertible Securities Reclassified As Treasury Stock Value SharesWithheldUponConversionOfConvertibleSecuritiesReclassifiedAsTreasuryStockValue	18331000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	66048000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	69458000	usd
CY2023Q3	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	11651000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	11651000	usd
CY2023Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	9664000	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	9664000	usd
CY2023Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	25731000	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	24959000	usd
CY2023Q3	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	35745000	usd
CY2022Q4	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	36963000	usd
CY2023Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	8701000	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	86118000	usd
CY2023Q3	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	8589000	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	0	usd
CY2023Q3	amr	Accrued Transportation Costs Current AccruedTransportationCostsCurrent	12378000	usd
CY2022Q4	amr	Accrued Transportation Costs Current AccruedTransportationCostsCurrent	7181000	usd
CY2023Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	11612000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	19262000	usd
CY2023Q3	amr	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	190119000	usd
CY2022Q4	amr	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	265256000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	867849000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2499503000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	5726000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	6179000	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	4776000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4796000	usd
CY2023Q3	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	10502000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	10975000	usd
CY2023Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	3438000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	3078000	usd
CY2023Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	7064000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	7897000	usd
CY2023Q3	amr	Acquisition Related Obligations Carrying Amount Current AcquisitionRelatedObligationsCarryingAmountCurrent	181000	usd
CY2022Q4	amr	Acquisition Related Obligations Carrying Amount Current AcquisitionRelatedObligationsCarryingAmountCurrent	28254000	usd
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	179011000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	19129000	usd
	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	43000	usd
	us-gaap	Asset Retirement Obligation Liabilities Settled AssetRetirementObligationLiabilitiesSettled	14252000	usd
CY2023Q3	us-gaap	Asset Retirement Obligation AssetRetirementObligation	183845000	usd
CY2023Q3	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	35745000	usd
CY2023Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	148100000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	46052000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	105735000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94973000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	640913000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	113953000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1341818000	usd
CY2023Q3	amr	Medical Self Insurance Period Expense MedicalSelfInsurancePeriodExpense	22040000	usd
CY2022Q3	amr	Medical Self Insurance Period Expense MedicalSelfInsurancePeriodExpense	18324000	usd
	amr	Medical Self Insurance Period Expense MedicalSelfInsurancePeriodExpense	61866000	usd
	amr	Medical Self Insurance Period Expense MedicalSelfInsurancePeriodExpense	49334000	usd
CY2023Q3	us-gaap	Royalty Expense RoyaltyExpense	39284000	usd
CY2022Q3	us-gaap	Royalty Expense RoyaltyExpense	44340000	usd
	us-gaap	Royalty Expense RoyaltyExpense	136308000	usd
	us-gaap	Royalty Expense RoyaltyExpense	174310000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	83004000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	53488000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	24547000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	83004000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	28941000	usd
CY2023Q3	us-gaap	Restricted Investments RestrictedInvestments	71269000	usd
CY2022Q4	us-gaap	Restricted Investments RestrictedInvestments	105735000	usd
CY2023Q3	us-gaap	Deposit Assets DepositAssets	7605000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	86111000	usd
CY2023Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	6736000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	84748000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	869000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3271845000	usd
CY2023Q3	us-gaap	Revenues Revenues	741820000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1363000	usd
CY2023Q3	amr	Deposits Dividends DepositsDividends	6736000	usd
CY2022Q4	amr	Deposits Dividends DepositsDividends	84748000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q3	us-gaap	Revenues Revenues	741820000	usd
CY2023Q3	amr	Depreciation Depletion And Amortization Excluding Acquired Intangibles DepreciationDepletionAndAmortizationExcludingAcquiredIntangibles	32582000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2069000	usd
CY2023Q3	amr	Adjusted Earnings Before Income Tax Interest Depreciation And Amortization AdjustedEarningsBeforeIncomeTaxInterestDepreciationAndAmortization	153911000	usd
CY2023Q3	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	54725000	usd
CY2022Q3	us-gaap	Revenues Revenues	869768000	usd
CY2022Q3	amr	Depreciation Depletion And Amortization Excluding Acquired Intangibles DepreciationDepletionAndAmortizationExcludingAcquiredIntangibles	27925000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4543000	usd
CY2022Q3	amr	Adjusted Earnings Before Income Tax Interest Depreciation And Amortization AdjustedEarningsBeforeIncomeTaxInterestDepreciationAndAmortization	296198000	usd
CY2022Q3	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	33339000	usd
	us-gaap	Revenues Revenues	2511426000	usd
	amr	Depreciation Depletion And Amortization Excluding Acquired Intangibles DepreciationDepletionAndAmortizationExcludingAcquiredIntangibles	94231000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6458000	usd
	amr	Adjusted Earnings Before Income Tax Interest Depreciation And Amortization AdjustedEarningsBeforeIncomeTaxInterestDepreciationAndAmortization	766820000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	183836000	usd
	us-gaap	Revenues Revenues	3278144000	usd
	amr	Depreciation Depletion And Amortization Excluding Acquired Intangibles DepreciationDepletionAndAmortizationExcludingAcquiredIntangibles	83690000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16038000	usd
	amr	Adjusted Earnings Before Income Tax Interest Depreciation And Amortization AdjustedEarningsBeforeIncomeTaxInterestDepreciationAndAmortization	1492729000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	103351000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	93814000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18964000	usd
CY2023Q3	amr	Depreciation Depletion And Amortization Excluding Acquired Intangibles DepreciationDepletionAndAmortizationExcludingAcquiredIntangibles	32582000	usd
CY2023Q3	amr	Noncash Allocated Sharebased Compensation Expense NoncashAllocatedSharebasedCompensationExpense	2999000	usd
CY2023Q3	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	6376000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2069000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	545940000	usd
	us-gaap	Interest Expense InterestExpense	5322000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8911000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94973000	usd
	amr	Depreciation Depletion And Amortization Excluding Acquired Intangibles DepreciationDepletionAndAmortizationExcludingAcquiredIntangibles	94231000	usd
	amr	Noncash Allocated Sharebased Compensation Expense NoncashAllocatedSharebasedCompensationExpense	9678000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	19129000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6458000	usd
	amr	Adjusted Earnings Before Income Tax Interest Depreciation And Amortization AdjustedEarningsBeforeIncomeTaxInterestDepreciationAndAmortization	766820000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1227865000	usd
	us-gaap	Interest Expense InterestExpense	20055000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1412000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	113953000	usd
	amr	Depreciation Depletion And Amortization Excluding Acquired Intangibles DepreciationDepletionAndAmortizationExcludingAcquiredIntangibles	83690000	usd
	amr	Noncash Allocated Sharebased Compensation Expense NoncashAllocatedSharebasedCompensationExpense	4103000	usd
	amr	Acquisition Related Obligations Changes In Fair Value Gain Loss AcquisitionRelatedObligationsChangesInFairValueGainLoss	-10615000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	17822000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16038000	usd
	amr	Adjusted Earnings Before Income Tax Interest Depreciation And Amortization AdjustedEarningsBeforeIncomeTaxInterestDepreciationAndAmortization	1492729000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	738998000	usd
CY2022Q3	us-gaap	Revenues Revenues	869768000	usd
	us-gaap	Revenues Revenues	2511426000	usd
	us-gaap	Revenues Revenues	3278144000	usd
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001704715-23-000066-index-headers.html	Edgar Link	pending
0001704715-23-000066-index.html	Edgar Link	pending
0001704715-23-000066.txt	Edgar Link	pending
0001704715-23-000066-xbrl.zip	Edgar Link	pending
a9302023exhibit31.htm	Edgar Link	pending
a9302023exhibit32.htm	Edgar Link	pending
a9302023exhibit95.htm	Edgar Link	pending
amr-20230930.htm	Edgar Link	pending
amr-20230930.xsd	Edgar Link	pending
amr-20230930_g1.jpg	Edgar Link	pending
exhibit101alphacreditagr.htm	Edgar Link	pending
exhibit101alphacreditagr001.jpg	Edgar Link	pending
exhibit101alphacreditagr002.jpg	Edgar Link	pending
amr-20230930_cal.xml	Edgar Link	unprocessable
amr-20230930_def.xml	Edgar Link	unprocessable
amr-20230930_lab.xml	Edgar Link	unprocessable
amr-20230930_pre.xml	Edgar Link	unprocessable
amr-20230930_htm.xml	Edgar Link	completed
exhibit101alphacreditagr003.jpg	Edgar Link	pending
exhibit101alphacreditagr004.jpg	Edgar Link	pending
exhibit101alphacreditagr005.jpg	Edgar Link	pending
exhibit101alphacreditagr006.jpg	Edgar Link	pending
exhibit101alphacreditagr007.jpg	Edgar Link	pending
exhibit101alphacreditagr008.jpg	Edgar Link	pending
exhibit101alphacreditagr009.jpg	Edgar Link	pending
exhibit101alphacreditagr010.jpg	Edgar Link	pending
exhibit101alphacreditagr011.jpg	Edgar Link	pending
exhibit101alphacreditagr012.jpg	Edgar Link	pending
exhibit101alphacreditagr013.jpg	Edgar Link	pending
exhibit101alphacreditagr014.jpg	Edgar Link	pending
exhibit101alphacreditagr015.jpg	Edgar Link	pending
exhibit101alphacreditagr016.jpg	Edgar Link	pending
exhibit101alphacreditagr017.jpg	Edgar Link	pending
exhibit101alphacreditagr018.jpg	Edgar Link	pending
exhibit101alphacreditagr019.jpg	Edgar Link	pending
exhibit101alphacreditagr020.jpg	Edgar Link	pending
exhibit101alphacreditagr021.jpg	Edgar Link	pending
exhibit101alphacreditagr022.jpg	Edgar Link	pending
exhibit101alphacreditagr023.jpg	Edgar Link	pending
exhibit101alphacreditagr024.jpg	Edgar Link	pending
exhibit101alphacreditagr025.jpg	Edgar Link	pending
exhibit101alphacreditagr026.jpg	Edgar Link	pending
exhibit101alphacreditagr027.jpg	Edgar Link	pending
exhibit101alphacreditagr028.jpg	Edgar Link	pending
exhibit101alphacreditagr029.jpg	Edgar Link	pending
exhibit101alphacreditagr030.jpg	Edgar Link	pending
exhibit101alphacreditagr031.jpg	Edgar Link	pending
exhibit101alphacreditagr032.jpg	Edgar Link	pending
exhibit101alphacreditagr033.jpg	Edgar Link	pending
exhibit101alphacreditagr034.jpg	Edgar Link	pending
exhibit101alphacreditagr035.jpg	Edgar Link	pending
exhibit101alphacreditagr036.jpg	Edgar Link	pending
exhibit101alphacreditagr037.jpg	Edgar Link	pending
exhibit101alphacreditagr038.jpg	Edgar Link	pending
exhibit101alphacreditagr039.jpg	Edgar Link	pending
exhibit101alphacreditagr040.jpg	Edgar Link	pending
exhibit101alphacreditagr041.jpg	Edgar Link	pending
exhibit101alphacreditagr042.jpg	Edgar Link	pending
exhibit101alphacreditagr043.jpg	Edgar Link	pending
exhibit101alphacreditagr044.jpg	Edgar Link	pending
exhibit101alphacreditagr045.jpg	Edgar Link	pending
exhibit101alphacreditagr046.jpg	Edgar Link	pending
exhibit101alphacreditagr047.jpg	Edgar Link	pending
exhibit101alphacreditagr048.jpg	Edgar Link	pending
exhibit101alphacreditagr049.jpg	Edgar Link	pending
exhibit101alphacreditagr050.jpg	Edgar Link	pending
exhibit101alphacreditagr051.jpg	Edgar Link	pending
exhibit101alphacreditagr052.jpg	Edgar Link	pending
exhibit101alphacreditagr053.jpg	Edgar Link	pending
exhibit101alphacreditagr054.jpg	Edgar Link	pending
exhibit101alphacreditagr055.jpg	Edgar Link	pending
exhibit101alphacreditagr056.jpg	Edgar Link	pending
exhibit101alphacreditagr057.jpg	Edgar Link	pending
exhibit101alphacreditagr058.jpg	Edgar Link	pending
exhibit101alphacreditagr059.jpg	Edgar Link	pending
exhibit101alphacreditagr060.jpg	Edgar Link	pending
exhibit101alphacreditagr061.jpg	Edgar Link	pending
exhibit101alphacreditagr062.jpg	Edgar Link	pending
exhibit101alphacreditagr063.jpg	Edgar Link	pending
exhibit101alphacreditagr064.jpg	Edgar Link	pending
exhibit101alphacreditagr065.jpg	Edgar Link	pending
exhibit101alphacreditagr066.jpg	Edgar Link	pending
exhibit101alphacreditagr067.jpg	Edgar Link	pending
exhibit101alphacreditagr068.jpg	Edgar Link	pending
exhibit101alphacreditagr069.jpg	Edgar Link	pending
exhibit101alphacreditagr070.jpg	Edgar Link	pending
exhibit101alphacreditagr071.jpg	Edgar Link	pending
exhibit101alphacreditagr072.jpg	Edgar Link	pending
exhibit101alphacreditagr073.jpg	Edgar Link	pending
exhibit101alphacreditagr074.jpg	Edgar Link	pending
exhibit101alphacreditagr075.jpg	Edgar Link	pending
exhibit101alphacreditagr076.jpg	Edgar Link	pending
exhibit101alphacreditagr077.jpg	Edgar Link	pending
exhibit101alphacreditagr078.jpg	Edgar Link	pending
exhibit101alphacreditagr079.jpg	Edgar Link	pending
exhibit101alphacreditagr080.jpg	Edgar Link	pending
exhibit101alphacreditagr081.jpg	Edgar Link	pending
exhibit101alphacreditagr082.jpg	Edgar Link	pending
exhibit101alphacreditagr083.jpg	Edgar Link	pending
exhibit101alphacreditagr084.jpg	Edgar Link	pending
exhibit101alphacreditagr085.jpg	Edgar Link	pending
exhibit101alphacreditagr086.jpg	Edgar Link	pending
exhibit101alphacreditagr087.jpg	Edgar Link	pending
exhibit101alphacreditagr088.jpg	Edgar Link	pending
exhibit101alphacreditagr089.jpg	Edgar Link	pending
exhibit101alphacreditagr090.jpg	Edgar Link	pending
exhibit101alphacreditagr091.jpg	Edgar Link	pending
exhibit101alphacreditagr092.jpg	Edgar Link	pending
exhibit101alphacreditagr093.jpg	Edgar Link	pending
exhibit101alphacreditagr094.jpg	Edgar Link	pending
exhibit101alphacreditagr095.jpg	Edgar Link	pending
exhibit101alphacreditagr096.jpg	Edgar Link	pending
exhibit101alphacreditagr097.jpg	Edgar Link	pending
exhibit101alphacreditagr098.jpg	Edgar Link	pending
exhibit101alphacreditagr099.jpg	Edgar Link	pending
exhibit101alphacreditagr100.jpg	Edgar Link	pending
exhibit101alphacreditagr101.jpg	Edgar Link	pending
exhibit101alphacreditagr102.jpg	Edgar Link	pending
exhibit101alphacreditagr103.jpg	Edgar Link	pending
exhibit101alphacreditagr104.jpg	Edgar Link	pending
exhibit101alphacreditagr105.jpg	Edgar Link	pending
exhibit101alphacreditagr106.jpg	Edgar Link	pending
exhibit101alphacreditagr107.jpg	Edgar Link	pending
exhibit101alphacreditagr108.jpg	Edgar Link	pending
exhibit101alphacreditagr109.jpg	Edgar Link	pending
exhibit101alphacreditagr110.jpg	Edgar Link	pending
exhibit101alphacreditagr111.jpg	Edgar Link	pending
exhibit101alphacreditagr112.jpg	Edgar Link	pending
exhibit101alphacreditagr113.jpg	Edgar Link	pending
exhibit101alphacreditagr114.jpg	Edgar Link	pending
exhibit101alphacreditagr115.jpg	Edgar Link	pending
exhibit101alphacreditagr116.jpg	Edgar Link	pending
exhibit101alphacreditagr117.jpg	Edgar Link	pending
exhibit101alphacreditagr118.jpg	Edgar Link	pending
exhibit101alphacreditagr119.jpg	Edgar Link	pending
exhibit101alphacreditagr120.jpg	Edgar Link	pending
exhibit101alphacreditagr121.jpg	Edgar Link	pending
exhibit101alphacreditagr122.jpg	Edgar Link	pending
exhibit101alphacreditagr123.jpg	Edgar Link	pending
exhibit101alphacreditagr124.jpg	Edgar Link	pending
exhibit101alphacreditagr125.jpg	Edgar Link	pending
exhibit101alphacreditagr126.jpg	Edgar Link	pending
exhibit101alphacreditagr127.jpg	Edgar Link	pending
exhibit101alphacreditagr128.jpg	Edgar Link	pending
exhibit101alphacreditagr129.jpg	Edgar Link	pending
exhibit101alphacreditagr130.jpg	Edgar Link	pending
exhibit101alphacreditagr131.jpg	Edgar Link	pending
exhibit101alphacreditagr132.jpg	Edgar Link	pending
exhibit101alphacreditagr133.jpg	Edgar Link	pending
exhibit101alphacreditagr134.jpg	Edgar Link	pending
exhibit101alphacreditagr135.jpg	Edgar Link	pending
exhibit101alphacreditagr136.jpg	Edgar Link	pending
exhibit101alphacreditagr137.jpg	Edgar Link	pending
exhibit101alphacreditagr138.jpg	Edgar Link	pending
exhibit101alphacreditagr139.jpg	Edgar Link	pending
exhibit101alphacreditagr140.jpg	Edgar Link	pending
exhibit101alphacreditagr141.jpg	Edgar Link	pending
exhibit101alphacreditagr142.jpg	Edgar Link	pending
exhibit101alphacreditagr143.jpg	Edgar Link	pending
exhibit101alphacreditagr144.jpg	Edgar Link	pending
exhibit101alphacreditagr145.jpg	Edgar Link	pending
exhibit101alphacreditagr146.jpg	Edgar Link	pending
exhibit101alphacreditagr147.jpg	Edgar Link	pending
exhibit101alphacreditagr148.jpg	Edgar Link	pending
exhibit101alphacreditagr149.jpg	Edgar Link	pending
exhibit101alphacreditagr150.jpg	Edgar Link	pending
exhibit101alphacreditagr151.jpg	Edgar Link	pending
exhibit101alphacreditagr152.jpg	Edgar Link	pending
exhibit101alphacreditagr153.jpg	Edgar Link	pending
exhibit101alphacreditagr154.jpg	Edgar Link	pending
exhibit101alphacreditagr155.jpg	Edgar Link	pending
exhibit101alphacreditagr156.jpg	Edgar Link	pending
exhibit101alphacreditagr157.jpg	Edgar Link	pending
exhibit101alphacreditagr158.jpg	Edgar Link	pending
exhibit101alphacreditagr159.jpg	Edgar Link	pending
exhibit101alphacreditagr160.jpg	Edgar Link	pending
exhibit101alphacreditagr161.jpg	Edgar Link	pending
exhibit101alphacreditagr162.jpg	Edgar Link	pending
exhibit101alphacreditagr163.jpg	Edgar Link	pending
exhibit101alphacreditagr164.jpg	Edgar Link	pending
exhibit101alphacreditagr165.jpg	Edgar Link	pending
exhibit101alphacreditagr166.jpg	Edgar Link	pending
exhibit101alphacreditagr167.jpg	Edgar Link	pending
exhibit101alphacreditagr168.jpg	Edgar Link	pending
exhibit101alphacreditagr169.jpg	Edgar Link	pending
exhibit101alphacreditagr170.jpg	Edgar Link	pending
exhibit101alphacreditagr171.jpg	Edgar Link	pending
exhibit101alphacreditagr172.jpg	Edgar Link	pending
exhibit101alphacreditagr173.jpg	Edgar Link	pending
exhibit101alphacreditagr174.jpg	Edgar Link	pending
exhibit101alphacreditagr175.jpg	Edgar Link	pending
exhibit101alphacreditagr176.jpg	Edgar Link	pending
exhibit101alphacreditagr177.jpg	Edgar Link	pending
exhibit101alphacreditagr178.jpg	Edgar Link	pending
exhibit101alphacreditagr179.jpg	Edgar Link	pending
exhibit101alphacreditagr180.jpg	Edgar Link	pending
exhibit101alphacreditagr181.jpg	Edgar Link	pending
exhibit101alphacreditagr182.jpg	Edgar Link	pending
exhibit101alphacreditagr183.jpg	Edgar Link	pending
exhibit101alphacreditagr184.jpg	Edgar Link	pending
exhibit101alphacreditagr185.jpg	Edgar Link	pending
exhibit101alphacreditagr186.jpg	Edgar Link	pending
exhibit101alphacreditagr187.jpg	Edgar Link	pending
exhibit101alphacreditagr188.jpg	Edgar Link	pending
exhibit101alphacreditagr189.jpg	Edgar Link	pending
exhibit101alphacreditagr190.jpg	Edgar Link	pending
exhibit101alphacreditagr191.jpg	Edgar Link	pending
exhibit101alphacreditagr192.jpg	Edgar Link	pending
exhibit101alphacreditagr193.jpg	Edgar Link	pending
exhibit101alphacreditagr194.jpg	Edgar Link	pending
exhibit101alphacreditagr195.jpg	Edgar Link	pending
exhibit101alphacreditagr196.jpg	Edgar Link	pending
exhibit101alphacreditagr197.jpg	Edgar Link	pending
exhibit101alphacreditagr198.jpg	Edgar Link	pending
exhibit101alphacreditagr199.jpg	Edgar Link	pending
exhibit101alphacreditagr200.jpg	Edgar Link	pending
exhibit101alphacreditagr201.jpg	Edgar Link	pending
exhibit101alphacreditagr202.jpg	Edgar Link	pending
exhibit101alphacreditagr203.jpg	Edgar Link	pending
exhibit101alphacreditagr204.jpg	Edgar Link	pending
exhibit101alphacreditagr205.jpg	Edgar Link	pending
exhibit101alphacreditagr206.jpg	Edgar Link	pending
exhibit101alphacreditagr207.jpg	Edgar Link	pending
exhibit101alphacreditagr208.jpg	Edgar Link	pending
exhibit101alphacreditagr209.jpg	Edgar Link	pending
exhibit101alphacreditagr210.jpg	Edgar Link	pending
exhibit101alphacreditagr211.jpg	Edgar Link	pending
exhibit101alphacreditagr212.jpg	Edgar Link	pending
exhibit101alphacreditagr213.jpg	Edgar Link	pending
exhibit101alphacreditagr214.jpg	Edgar Link	pending
exhibit101alphacreditagr215.jpg	Edgar Link	pending
exhibit101alphacreditagr216.jpg	Edgar Link	pending
exhibit101alphacreditagr217.jpg	Edgar Link	pending
exhibit101alphacreditagr218.jpg	Edgar Link	pending
exhibit101alphacreditagr219.jpg	Edgar Link	pending
exhibit101alphacreditagr220.jpg	Edgar Link	pending
exhibit101alphacreditagr221.jpg	Edgar Link	pending
exhibit101alphacreditagr222.jpg	Edgar Link	pending
exhibit101alphacreditagr223.jpg	Edgar Link	pending
exhibit101alphacreditagr224.jpg	Edgar Link	pending
exhibit101alphacreditagr225.jpg	Edgar Link	pending
exhibit101alphacreditagr226.jpg	Edgar Link	pending
exhibit101alphacreditagr227.jpg	Edgar Link	pending
exhibit101alphacreditagr228.jpg	Edgar Link	pending
exhibit101alphacreditagr229.jpg	Edgar Link	pending
exhibit101alphacreditagr230.jpg	Edgar Link	pending
exhibit101alphacreditagr231.jpg	Edgar Link	pending
exhibit101alphacreditagr232.jpg	Edgar Link	pending
exhibit101alphacreditagr233.jpg	Edgar Link	pending
exhibit101alphacreditagr234.jpg	Edgar Link	pending
exhibit101alphacreditagr235.jpg	Edgar Link	pending
exhibit101alphacreditagr236.jpg	Edgar Link	pending
exhibit101alphacreditagr237.jpg	Edgar Link	pending
exhibit101alphacreditagr238.jpg	Edgar Link	pending
exhibit101alphacreditagr239.jpg	Edgar Link	pending
exhibit101alphacreditagr240.jpg	Edgar Link	pending
exhibit101alphacreditagr241.jpg	Edgar Link	pending
exhibit101alphacreditagr242.jpg	Edgar Link	pending
exhibit101alphacreditagr243.jpg	Edgar Link	pending
exhibit101alphacreditagr244.jpg	Edgar Link	pending
exhibit101alphacreditagr245.jpg	Edgar Link	pending
exhibit101alphacreditagr246.jpg	Edgar Link	pending
exhibit101alphacreditagr247.jpg	Edgar Link	pending
exhibit101alphacreditagr248.jpg	Edgar Link	pending
exhibit101alphacreditagr249.jpg	Edgar Link	pending
exhibit101alphacreditagr250.jpg	Edgar Link	pending
exhibit101alphacreditagr251.jpg	Edgar Link	pending
exhibit101alphacreditagr252.jpg	Edgar Link	pending
exhibit101alphacreditagr253.jpg	Edgar Link	pending
exhibit101alphacreditagr254.jpg	Edgar Link	pending
exhibit101alphacreditagr255.jpg	Edgar Link	pending
exhibit101alphacreditagr256.jpg	Edgar Link	pending
exhibit101alphacreditagr257.jpg	Edgar Link	pending
exhibit101alphacreditagr258.jpg	Edgar Link	pending
exhibit101alphacreditagr259.jpg	Edgar Link	pending
exhibit101alphacreditagr260.jpg	Edgar Link	pending
exhibit101alphacreditagr261.jpg	Edgar Link	pending
exhibit101alphacreditagr262.jpg	Edgar Link	pending
exhibit101alphacreditagr263.jpg	Edgar Link	pending
exhibit101alphacreditagr264.jpg	Edgar Link	pending
exhibit101alphacreditagr265.jpg	Edgar Link	pending
exhibit101alphacreditagr266.jpg	Edgar Link	pending
exhibit101alphacreditagr267.jpg	Edgar Link	pending
exhibit101alphacreditagr268.jpg	Edgar Link	pending
exhibit101alphacreditagr269.jpg	Edgar Link	pending
exhibit101alphacreditagr270.jpg	Edgar Link	pending
exhibit101alphacreditagr271.jpg	Edgar Link	pending
exhibit101alphacreditagr272.jpg	Edgar Link	pending
exhibit101alphacreditagr273.jpg	Edgar Link	pending
exhibit102alphasecuritya.htm	Edgar Link	pending
exhibit102alphasecuritya001.jpg	Edgar Link	pending
exhibit102alphasecuritya002.jpg	Edgar Link	pending
exhibit102alphasecuritya003.jpg	Edgar Link	pending
exhibit102alphasecuritya004.jpg	Edgar Link	pending
exhibit102alphasecuritya005.jpg	Edgar Link	pending
exhibit102alphasecuritya006.jpg	Edgar Link	pending
exhibit102alphasecuritya007.jpg	Edgar Link	pending
exhibit102alphasecuritya008.jpg	Edgar Link	pending
exhibit102alphasecuritya009.jpg	Edgar Link	pending
exhibit102alphasecuritya010.jpg	Edgar Link	pending
exhibit102alphasecuritya011.jpg	Edgar Link	pending
exhibit102alphasecuritya012.jpg	Edgar Link	pending
exhibit102alphasecuritya013.jpg	Edgar Link	pending
exhibit102alphasecuritya014.jpg	Edgar Link	pending
exhibit102alphasecuritya015.jpg	Edgar Link	pending
exhibit102alphasecuritya016.jpg	Edgar Link	pending
exhibit102alphasecuritya017.jpg	Edgar Link	pending
exhibit102alphasecuritya018.jpg	Edgar Link	pending
exhibit102alphasecuritya019.jpg	Edgar Link	pending
exhibit102alphasecuritya020.jpg	Edgar Link	pending
exhibit102alphasecuritya021.jpg	Edgar Link	pending
exhibit102alphasecuritya022.jpg	Edgar Link	pending
exhibit102alphasecuritya023.jpg	Edgar Link	pending
exhibit102alphasecuritya024.jpg	Edgar Link	pending
exhibit102alphasecuritya025.jpg	Edgar Link	pending
exhibit102alphasecuritya026.jpg	Edgar Link	pending
exhibit102alphasecuritya027.jpg	Edgar Link	pending
exhibit102alphasecuritya028.jpg	Edgar Link	pending
exhibit102alphasecuritya029.jpg	Edgar Link	pending
exhibit102alphasecuritya030.jpg	Edgar Link	pending
exhibit102alphasecuritya031.jpg	Edgar Link	pending
exhibit102alphasecuritya032.jpg	Edgar Link	pending
exhibit102alphasecuritya033.jpg	Edgar Link	pending
exhibit102alphasecuritya034.jpg	Edgar Link	pending
exhibit102alphasecuritya035.jpg	Edgar Link	pending
exhibit102alphasecuritya036.jpg	Edgar Link	pending
exhibit102alphasecuritya037.jpg	Edgar Link	pending
exhibit102alphasecuritya038.jpg	Edgar Link	pending
exhibit102alphasecuritya039.jpg	Edgar Link	pending
exhibit102alphasecuritya040.jpg	Edgar Link	pending
exhibit102alphasecuritya041.jpg	Edgar Link	pending
exhibit102alphasecuritya042.jpg	Edgar Link	pending
exhibit102alphasecuritya043.jpg	Edgar Link	pending
exhibit102alphasecuritya044.jpg	Edgar Link	pending
exhibit102alphasecuritya045.jpg	Edgar Link	pending
exhibit102alphasecuritya046.jpg	Edgar Link	pending
exhibit102alphasecuritya047.jpg	Edgar Link	pending
exhibit102alphasecuritya048.jpg	Edgar Link	pending
exhibit102alphasecuritya049.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMR
Alpha Metallurgical Resources, Inc. Stock $amr

2023 Q4 Form 10-Q Financial Statement

#000170471523000066 Filed on November 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMR Alpha Metallurgical Resources, Inc. Stock $amr

2023 Q4 Form 10-Q Financial Statement

#000170471523000066 Filed on November 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMR
Alpha Metallurgical Resources, Inc. Stock $amr